Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

OmRx Oncology (OmRx) has commenced a Phase II trial for its OX-4224, targeting individuals with non-small cell lung cancer ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

It is vital for biotech companies to run the right clinical trial and not cut costs, the Sanofi executive said.

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial of bulevirtide for adults with chronic hepatitis ...

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for ...

AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with ABO21009, aimed at treating rheumatoid arthritis (RA ...

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.